Skip to main content
. 2021 May;9(10):913. doi: 10.21037/atm-20-5032

Table 3. Baseline characteristics after matching.

Variable Cis q3wk Cis q1wk P Cis q3wk Other P No ICT ICT P
N % N % N % N % N % N %
Gender 0.89 0.86 0.36
   Male 153 84 151 83 74 79 76 81 47 92 43 84
   Female 30 16 32 17 20 21 18 19 4 8 8 16
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Age (yrs) 0.30 0.88 1
   <61 101 55 90 49 46 49 44 47 33 65 33 65
   ≥61 82 45 93 51 48 51 50 53 18 35 18 35
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Smoker 0.40 0.45 0.42
   Never 45 25 35 19 16 17 14 15 14 27 8 16
   Former 83 45 85 46 63 67 58 62 17 33 20 39
   Current 55 30 63 34 15 16 22 23 20 39 23 45
   Total 183 100 183 100 94 100 94 100 51 100 51 100
HPV 0.20 0.93 0.82
   Negative 37 20 49 27 18 19 20 21 12 24 15 29
   Positive 73 40 59 32 30 32 31 33 18 35 17 33
   NA 73 40 75 41 46 49 43 46 21 41 19 37
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Comorbidity (no.) 0.82 0.89 1
   0 41 22 41 22 11 12 10 11 12 24 13 25
   1 57 31 49 27 27 29 26 28 17 33 16 31
   2 43 23 47 26 30 32 27 29 11 22 10 20
   3+ 42 23 46 25 26 28 31 33 11 22 12 24
   Total 183 100 183 100 94 100 94 100 51 100 51 100
T stage 0.46 0.61 1
   X 0 0 0 0 0 0 1 1 0 0 0 0
   0–2 89 49 77 42 46 49 50 53 17 33 17 33
   3–4 93 51 105 57 47 50 43 46 32 63 33 65
   NA 1 1 1 1 1 1 0 0 2 4 1 2
   Total 183 100 183 100 94 100 94 100 51 100 51 100
N stage 0.71 0.66 1
   0–1 50 27 58 32 42 45 39 41 10 20 11 22
   2–3 132 72 124 68 51 54 55 59 39 76 39 76
   NA 1 1 1 1 1 1 0 0 2 4 1 2
   Total 183 100 183 100 94 100 94 100 51 100 51 100
M stage 1 1 1
   0 178 97 178 97 91 97 91 97 47 92 48 94
   1 4 2 4 2 2 2 3 3 2 4 2 4
   NA 1 1 1 1 1 1 0 0 2 4 1 2
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Primary site 0.97 0.99 1
   NA 18 10 26 14 11 12 9 10 6 12 7 14
   Oral cavity 22 12 21 11 9 10 7 7 2 4 2 4
   Nasopharynx 2 1 2 1 3 3 2 2 1 2 2 4
   Oropharynx 77 42 70 38 47 50 46 49 24 47 19 37
   Hypopharynx 12 7 14 8 4 4 4 4 5 10 7 14
   Glottis 20 11 20 11 11 12 13 14 2 4 3 6
   Salivary 2 1 3 2 1 1 2 2 1 2 1 2
   Other 0 0 0 0 0 0 0 0 1 2 1 2
   Unknown 17 9 15 8 5 5 7 7 4 8 4 8
   Multiple 13 7 12 7 3 3 4 4 5 10 5 10
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Histology 1 1 1
   Squamous 178 97 177 97 90 96 91 97 49 96 50 98
   Other 5 3 6 3 4 4 3 3 2 4 1 2
   Total 183 100 183 100 94 100 94 100 51 100 51 100
RT type 0.90 1 NA
   Definitive 147 80 145 79 79 84 79 84 51 100 51 100
   Adjuvant 36 20 38 21 15 16 15 16 0 0 0 0
   Total 183 100 183 100 94 100 94 100 51 100 51 100
RT total dose (Gy) 0.53 0.83 0.69
   Median 70 70 70 70 70 70
   IQR 70–70 70–70 70–70 70–70 70–70 70–70
RT start year 1 0.88 0.84
   <2011 48 26 47 26 29 31 31 33 25 49 23 45
   ≥2011 135 74 136 74 65 69 63 67 26 51 28 55
   Total 183 100 183 100 94 100 94 100 51 100 51 100
RT complete 0.08 0.62 1
   No 2 1 9 5 2 2 1 1 2 4 2 4
   Yes 179 98 173 95 91 97 93 99 49 96 49 96
   NA 2 1 1 1 1 1 0 0 0 0 0 0
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Treatment response 0.65 0.86 0.97
   No response 5 3 6 3 6 6 4 4 4 8 3 6
   Partial 148 81 138 75 69 73 69 73 35 69 37 73
   Complete 17 9 21 11 9 10 12 13 8 16 8 16
   NA 13 7 18 10 10 11 9 10 4 8 3 6
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Surgery 1 0.71 1
   No 142 78 142 78 75 80 78 83 50 98 51 100
   Yes 41 22 41 22 19 20 16 17 1 2 0 0
   Total 183 100 183 100 94 100 94 100 51 100 51 100
ICT 0.16 1 NA
   No 164 90 154 84 85 90 84 89 51 100 0 0
   Yes 19 10 29 16 9 10 10 11 0 0 51 100
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Chemotherapy NA NA 1
   Cis q3wk 183 100 0 0 94 100 0 0 18 35 18 35
   Cis q1wk 0 0 183 100 0 0 0 0 22 43 22 43
   Other 0 0 0 0 0 0 94 100 11 22 11 22
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Nut support 0.38 0.46 1
   No 68 37 59 32 40 43 34 36 21 41 21 41
   Yes 115 63 124 68 54 57 60 64 30 59 30 59
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Hospitalized 0.86 0.62 1
   No 140 77 136 74 71 76 67 71 45 88 44 86
   Yes 42 23 46 25 23 24 27 29 6 12 7 14
   NA 1 1 1 1 0 0 0 0 0 0 0 0
   Total 183 100 183 100 94 100 94 100 51 100 51 100
WBC count 0.64 0.32 0.79
   Normal 157 86 149 81 81 86 76 81 37 73 40 78
   Low 1 1 3 2 3 3 2 2 1 2 2 4
   High 16 9 20 11 5 5 12 13 8 16 5 10
   NA 9 5 11 6 5 5 4 4 5 10 4 8
   Total 183 100 183 100 94 100 94 100 51 100 51 100
Hgb (g/dL) 0.37 0.86 0.83
   ≥12 140 77 128 70 71 76 69 73 28 55 31 61
   <12 34 19 44 24 18 19 21 22 18 35 16 31
   NA 9 5 11 6 5 5 4 4 5 10 4 8
   Total 183 100 183 100 94 100 94 100 51 100 51 100

Cis, cisplatin; q3wk, once every 3 weeks; Q1wk, once every week; IC, induction chemotherapy; HPV, human papilloma virus; NA, not available; RT, radiotherapy; IQR, interquartile range; ICT, induction chemotherapy; Nut, nutrition; WBC, white blood cell; Hgb, hemoglobin